# NVAX catalysts: NOVAVAX INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/nvax/catalysts

> NOVAVAX INC (NVAX) has no upcoming catalysts in this calendar. The latest recorded is the NOVAVAX INC earnings report, November 5, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | NOVAVAX INC |
| Ticker | NVAX (Nasdaq) |
| SEC CIK | 1000694 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/nvax |

## Cash runway

Cash $622.4M as of 2026-09-30; quarterly burn $94.2M; about 19.8 months of runway at that rate (XBRL company facts, accession 0001000694-26-000022).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2023 | [Hummingbird (hummingbird) topline data readout](https://sec-api.dev/pdufa/hummingbird) | NVAX |  | completed, met | "In August 2023, we announced topline results from our Phase 2b/3 Hummingbird™ trial that met its primary endpoints in children aged 6 through 11 years demonstrating both tolerability and immunologic responses." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630.htm)) |
| November 12, 2024 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000040/a3q24earningspressrelease2.htm)) |
| Dec 2024 | [CoV2373 trial start](https://sec-api.dev/pdufa/cov2373) | NVAX |  | completed | "Initiated Phase 3 trial in December 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000110465925020023/tm258153d1_ex99-1.htm)) |
| Q1 2025 | [CoV2705 topline data readout](https://sec-api.dev/pdufa/cov2705) | NVAX |  | scheduled | "Topline data is expected in the first quarter of 2025 and is expected to support regulatory submissions in the U.S. and other jurisdictions for this and future variant strain formulations." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231.htm)) |
| February 27, 2025 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000006/q42024earningspressrelease.htm)) |
| mid-2025 | [NOVAVAX INC topline data readout](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | scheduled | "We anticipate topline data for this initial patient cohort by mid-2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000021/nvax-20250331.htm)) |
| April 1, 2025 | [CoV2601 NDA/BLA acceptance](https://sec-api.dev/pdufa/cov2601) | NVAX |  | completed | "In the U.S., we submitted a BLA for our prototype vaccine and NVX-CoV2601, and the U.S. FDA notified us that our BLA was accepted for review with a PDUFA date of April 1, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000021/nvax-20250331.htm)) |
| April 1, 2025 | [CoV2601 PDUFA date](https://sec-api.dev/pdufa/cov2601) | NVAX |  | scheduled | "In the U.S., we submitted a BLA for our prototype vaccine and NVX-CoV2601, and the U.S. FDA notified us that our BLA was accepted for review with a PDUFA date of April 1, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000021/nvax-20250331.htm)) |
| May 8, 2025 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports First Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000024/a1q25earningspressreleased.htm)) |
| May 16, 2025 | [Nuvaxovid (nuvaxovid) FDA approval](https://sec-api.dev/pdufa/nuvaxovid) | NVAX |  | completed, approved | "announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Biologics License Application ("BLA") for Nuvaxovid™ for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years and older and individuals 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1000694/000110465925050226/tm2515521d1_8k.htm)) |
| May 22, 2025 | [NOVAVAX INC FDA advisory committee meeting](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | scheduled | "Biological Products Advisory Committee meeting on May 22, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1000694/000110465925050226/tm2515521d1_8k.htm)) |
| August 6, 2025 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000031/a2q25earningspressreleasef.htm)) |
| August 27, 2025 | [Nuvaxovid (nuvaxovid) FDA approval](https://sec-api.dev/pdufa/nuvaxovid) | NVAX | COVID-19 in individuals 65 years of age and older, or 12 years | completed, approved | "Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration has approved the Nuvaxovid™ 2025-2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000110465925084049/tm2524511d2_ex99-1.htm)) |
| November 6, 2025 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000048/nvax3q25earningspressrelea.htm)) |
| December 24, 2025 | [Cic vaccine co-formulated tniv2 , sarscov-2 rs and matrix-m adjuvant primary completion](https://sec-api.dev/pdufa/cic-vaccine-co-formulated-tniv2-sarscov-2-rs-and-matrix-m-adjuvant) | NVAX | COVID-19 | completed | "NCT06291857 (A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-24 (ACTUAL); Lead Sponsor Novavax." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06291857)) |
| February 26, 2026 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000011/nvaxq4-25earningspressrele.htm)) |
| May 6, 2026 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports First Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000162828026030924/nvaxq1-26earningspressrele.htm)) |
| August 6, 2026 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Press Release Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000019/prfinal.htm)) |
| November 5, 2026 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000021/nvax3q26earningspressrelea.htm)) |

## Drugs

- [Cic vaccine co-formulated tniv2 , sarscov-2 rs and matrix-m adjuvant](https://sec-api.dev/pdufa/cic-vaccine-co-formulated-tniv2-sarscov-2-rs-and-matrix-m-adjuvant): COVID-19
- [CoV2373](https://sec-api.dev/pdufa/cov2373): 
- [CoV2601](https://sec-api.dev/pdufa/cov2601): 
- [CoV2705](https://sec-api.dev/pdufa/cov2705): 
- [Hummingbird (hummingbird)](https://sec-api.dev/pdufa/hummingbird): 
- [Nuvaxovid (nuvaxovid)](https://sec-api.dev/pdufa/nuvaxovid): covid-19 in individuals 65 years of age and older, or 12 years

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/nvax/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NVAX catalysts: NOVAVAX INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/nvax/catalysts

```bibtex
@misc{secapidev_companies_nvax_catalysts_20261116,
  title        = {NVAX catalysts: NOVAVAX INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/nvax/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_nvax_catalysts_20261116","title":"NVAX catalysts: NOVAVAX INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/nvax/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
